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Background: The epidermal growth factor receptor (EGFR) signaling system is frequently unbalanced in human
malignancies due to increased ligand production, receptor overexpression, receptor mutations, and/or cross-talk
with other receptor systems. For this reason, the EGFR is an attractive target for anticancer therapy. The epidermal
growth factor also plays an important role in regulating multiple facets of cutaneous wound healing, including
inflammation, wound contraction, proliferation, migration, and angiogenesis. In the Center of Molecular
Immunology, a cancer vaccine is produced (CIMAvax® EGF) that blocks the binding of EGF to its receptor. This
blockade causes a significant inverse association between the anti-EGF antibody titers and EGF concentration.
Around 1,500 patients with non-small cell lung cancer have been treated, showing that this vaccine is safe,
immunogenic, increases survival and improves quality of life. Taking into account the therapeutic benefits of
CIMAvax® EGF vaccination and the role of EGF-EGFR system in the wound healing process, we decided to conduct
a retrospective research with the aim of determining the effect to the CIMAvax® EGF vaccine on the wound healing
process in patients undergoing surgical treatment.
Methods: Medical records of 452 vaccinated patients were reviewed and only six patients receiving surgical
treatment were identified. Further information about these six patients was obtained from source documents,
including medical records and operative reports using an observational list that included different variables. Post-
surgical wound healing complications were identified using the National Cancer Institute Common Toxicity Criteria
for Adverse Events (NCI-CTC) version 3.0.
Results: None of the six patients operated on presented adverse events related to the wound healing, that is to
say, no wound dehiscence, wound infection, delayed wound healing, fistula formation, abscess formation or
hemorrhage/bleeding associated with surgery during treatment with CIMAvax® EGF occurred.
Conclusions: These results suggest that the use of CIMAvax® EGF does not produce a deleterious effect in the
wound healing process.
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The epidermal growth factor receptor (EGFR) signaling
system is frequently unbalanced in human malignancies due
to increased ligand production, receptor overexpression,
receptor mutations, and/or cross-talk with other receptor
systems [1-3]. Changes in EGFR status have been
linked to the development and maintenance of a malignant
phenotype and correlated with poor clinical prognosis [4].
For this reason, the EGFR is an attractive target for
anticancer therapy [5].
On the other hand, a series of experimental and clinical
studies have demonstrated a positive effect of EGF on
wound repair, regulating multiple facets of cutaneous
wound healing, including inflammation, wound contraction,
proliferation, migration, and angiogenesis [6-9].
CIMAvax-EGF is a therapeutic cancer vaccine produced
in the Center of Molecular Immunology, composed
by human recombinant epidermal growth factor
(EGF) conjugated to the carrier protein P64K from
Neisseria meningitides and emulsified in Montanide
ISA 51 (Seppic.http://www.seppic.com/index.html Puteaux
Cedex, FRANCE). The vaccine induces antibodies against
EGF, one of the most important ligands of the EGFR that
would block EGF-EGFR binding. This blockade causes a
significant inverse association between the anti-EGF anti-
body titers and EGF concentration [10]. So far, six clinical
trials have been concluded and around 1,500 patients have
been treated, showing that this vaccine is safe, immuno-
genic, increases survival and improves quality of life [10-14].
It has also been shown that chronic use of CIMAvax® EGF
ensures a better response without evidence of accumulative
toxicity [15]. However, the chronic use of this vaccine
increases the possibility that patients will need surgical
procedures during the vaccine treatment period.
Taking into account the therapeutic benefits of CIMAvax®
EGF vaccination and the role of the EGF-EGFR system in
the wound healing process, we decided to conduct a retro-
spective research with the aim of determining the effect of
the CIMAvax® EGF vaccine on the wound healing process
in patients undergoing surgical treatment.
Methods
The EGF cancer vaccine
The CIMAvax® EGF vaccine is produced in the Center of
Molecular Immunology, Havana, Cuba, in manufacturing
facilities validated according to the European Medicines
Agency (EMA) Good Manufacturing Practice standards. It
is compound or composed by human recombinant EGF
produced in yeast, and chemically conjugated to the P64K
Neisseria meningitidis recombinant protein, produced in
E. coli [15,16]. For protein conjugation, glutaraldehyde
(0. 05%) is added to the protein mixture allowing the
reaction for one hour; then, the conjugated moiety is puri-
fied by ultra-filtration/diafiltration and sterile filtered [17].The vaccine is composed of the chemically conjugated
EGF-P64k containing two EGF molecules per P64k
molecule. For preparations in which alum was used
as adjuvant, conjugates were mixed after filtration
with 2 mg/dose of alum. Adsorption is achieved by
constant stirring at room temperature for one hour
under sterile conditions. Montanide ISA 51 (Seppic.
http://www.seppic.com/index.html Puteaux Cedex, FRANCE)
is used as the adjuvant. The conjugate is mixed with
an equal volume of the adjuvant until emulsification
immediately before injection. Each vaccine dose contains 1
mg of protein. The product is released in the Quality
Control Direction of the Center of Molecular Immunology
according to manufacturer specifications which include
among others, HPLC for molecular species, potency
measured as immunogenicity in vaccinated mice
(in vivo test), sterility and appearance [18].
This EGF-based cancer vaccine obtained registration in
2008 by Sanitary Registration from The Cuban Regulatory
Agency, CECMED, for advanced non-small cell lung cancer
(NSCLC) at stage IIIB-IV (surgical treatment nontax). This
was the first registration of a therapeutic vaccine in Cuba
and also the first registration of a lung cancer vaccine in
the world [14]. It also was registered in Peru [19].
Patient selection and methods
The cohort of patients included in this analysis comes
from nine different clinical trials; all have been diagnosed
with advanced NSCLC patients (stage IIIB-IV). The
results of five of these clinical trials have been previously
published [10-14,18,20-22]. These studies were approved
by the Institutional Review Boards of the participating
centers and authorized by the Cuban Regulatory Agency.
All patients provided informed consent before inclusion
in the clinical trial.
To identify patients who had undergone surgical treat-
ment, medical records of 452 patients were reviewed. After
identification of patients (ID) who had received surgical
treatment, further information was obtained from source
documents, including medical records and operative reports
using an observational list that included different variables,
such as: ID of patients, age, race, toxic habits, personal
history, medication use, time between receiving vaccine and
surgery, time between last dose of vaccine and surgery, type
of surgery, time between surgery and next vaccination,
treatment schedule and adverse events related to wound
healing. The review of the medical records included patient
follow-up period as part of the clinical trials.
Although we took into account some of the risk factors
for reduced proper healing: age and race; harmful habits
such as smoking habit, alcoholism and drug abuse; personal
history (obesity, paraplegia, coagulopathies, coronary artery
disease, peripheral vascular disease, immunosuppression,
malnutrition and diabetes mellitus); use of certain drugs
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chemotherapeutic drugs and radiation therapy) [23,24],
the presence of these risk factors was not considered to
constitute exclusion criteria for this study.
Surgery was classified as minor surgery and major
surgery [25]. Minor surgery included any surgical procedure
not involving general anesthesia or respiratory assistance.
Major surgery included any surgical procedure involving
anesthesia or respiratory assistance; all operations involving
opening body cavities or in which severe hemorrhage was
possible; all potentially life-threatening conditions; and any
procedure with the potential to induce permanent anatomic
(physical) or physiological impairment and/or associated
with orthopedics or extensive tissue dissection.
Assessment of postsurgical wound healing complications
Postsurgical Wound Healing Complications were identified
using the National Cancer Institute Common Toxicity
Criteria for Adverse Events (NCI-CTC) version 3.0.
Search terms included, wound dehiscence, wound infection,
delayed wound healing, fistula formation, abscess formation
and post-operative hemorrhage/bleeding (post-operative
period is defined as ≤ 72 hours after surgery).
Results
From the 452 clinical records reviewed in the nine
clinical trials, only six patients out of three clinical
trials underwent surgical treatment. One of them
underwent two major surgical procedures. None had
wound healing complications.
A detailed description of each individual patient who
underwent a surgical process is presented below and
Table 1 summarizes these results.
Patient 1
A 63 year-old man, with moderate chronic obstructive
pulmonary disease. He was diagnosed with squamous
cell carcinoma of the right lung in May 2003 and started
vaccination in the same month. Three years later he was
diagnosed with a right vocal cord polyp. A biopsy of the
lesion showed squamous cell carcinoma and he underwent
a right cordectomy (major surgery). Twenty-two days
elapsed between last vaccination and surgery. Thirteen
days after surgery the patient resumed vaccination without
wound healing complications. The patient received the
following treatment schedule as part of the clinical trials:
cyclophosphamide (200 mg/m2 body surface (SC)) 72 hours
before the first vaccination, two doses (every 14 days) of
CIMAvax® EGF: 2,4 mg (0.6 mg per each injection site)
given intramuscularly. Eighteen days after the second
vaccination dose: chemotherapy: cisplatin 100 mg/Kg
vinblastine 6 mg/Kg (every 21 days for four to six cycles)
and one month after CIMAvax® EGF: 2,4 mg (0,6 mg pereach injection site) given intramuscular monthly as
re-immunizations doses.
Patient 2
A 70-year old man diagnosed with squamous cell carcinoma
of the left lung in July 2003. He started vaccination
in the same month and 45 months after initiation of ther-
apy, he underwent a total laryngectomy (major surgery) for
a left vocal cord tumor extending to the subglottis
(squamous cell carcinoma). He continued using CIMAvax®
EGF until 27 days before surgery and resumed this treat-
ment 93 days after the surgery. His skin wound healing
was unremarkable. This patient had received the same
treatment schedule as patient 1.
Patient 3
A 58-year old man required thoracotomy (major surgery)
without surgical resection of the lung nine months after
starting CIMAvax® EGF for adenocarcinoma of the lung.
Eighteen days after first surgery he underwent lobectomy
(major surgery). The time between last vaccination
and surgery was 32 days and 50 days respectively. Re-
vaccination with CIMAvax® EGF was not possible due
to deterioration of performance status. The wounds
healed without any complications.
This patient received cyclophosphamide (200 mg/m2 SC)
72 hours before the first vaccination, CIMAvax® EGF: 2.4
mg (0,6 mg per each injection site) given intramuscularly
every 14 days as induction doses and then monthly as
re-immunizations doses.
Patient 4
A 61 year-old man diagnosed with NSCLC was treated
with CIMAvax® EGF plus nimotuzumab (an anti-EGFR
monoclonal antibody) during seven months. Vaccination
was interrupted after performance status deterioration.
Fifty-one days after the last dose of CIMAvax® EGF and
fifty-seven days after the last dose of nimotuzumab, he
underwent a craniotomy (major surgery) due to a brain
metastasis without delayed wound healing.
The patient was treated with cyclophosphamide
(200 mg/m2 SC) 72 hours before the first vaccination,
CIMAvax® EGF: 2.4 mg (0,6 mg per each injection
site) given intramuscularly every 14 days for three
months and then monthly as re-immunization doses
plus nimotuzumab: 200 mg intravenous as 12 weekly
induction doses and then every 14 days.
Patient 5
A 66 year-old man with previous history of chronic
gastritis and chronic bullous emphysema. He underwent
inguinal hernia surgery (major surgery) thirty-two months
after starting CIMAvax® EGF treatment for NSCLC. He
was on treatment with CIMAvax® EGF without any
Table 1 Description of the behavior of different studied variables





































No 35 months 22 Days Right cordectomy
(Major surgery)
13 Days No
2 74 White Ex-smoker
(20 cigarettes
per day for 55 years)
No No 45 months 27 Days Total laryngectomy
(Major surgery)
93 Days No









5 66 White Ex-smoker (44 years) Chronic gastritis;
Chronic bullous
emphysema
No 32 months 11 Days Inguinal hernia
surgery (Major surgery)
17 Days No
6 75 Afro-American Ex-smoker No No 5 months 1 Day Minimum pleurotomy
(Minor surgery)
31 Days No
NA (not applicable): no possible resumption of CIMAvax® EGF treatment.
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and surgery and 17 days after the patient received the
next administration). The wound healed without any
complications.
As part of the clinical trials this patient received cyclo-
phosphamide (200 mg/m2 SC) 72 hours before the first
vaccination, CIMAvax® EGF: 2.4 mg (0.6 mg per each
injection site) given intramuscularly every 14 days for
three months and then as monthly re-immunizations
doses.
Patient 6
A 75 year-old woman required a minimum pleurotomy
(minor surgery) as a consequence of a pleural effusion
five months after starting CIMAvax® EGF for NSCLC.
She continued to use CIMAvax® EGF until the day
before surgery and resumed this vaccination 31 days after
the surgery. Her skin wound healing was unremarkable.
This patient received the same treatment schedule as that
of patient 5 .
Discussion
Growth factors represent the intercellular signaling that
orchestrates the complex sequence of cell migration,
division, differentiation, and protein expression during
wound healing and they are expressed in varying levels
by the cells involved with healing. As an essential part of
skin regeneration when injury has taken place, EGF
works by attracting cells to a wound site in order to
begin the repair process. The vital protein is released by
platelets during the inflammation stage of healing.
This protein supports cell renewal by assisting in the
synthesis of proteins, increasing circulation, mitosis,
the number of fibroblasts, the accumulation of collagen
and blood-vessel formation [26].
Several clinical trials have been carried out with
CIMAvax® EGF vaccine. In more than 1,500 patients
treated, there are no reports of wound dehiscence,
wound infection, delayed wound healing, fistula formation,
post-operative hemorrhage or any other adverse events
associated with post-surgical wound healing complications
[10-12], [20-22], [27], but no analysis or in-depth discussion
have been previously reported.
A previous non-clinical study investigated the possible
role of the EGF-vaccine in the croton-oil-induced ear edema
and, in the wound healing experimental animal models,
concluded that the EGF vaccination in mice decreased the
normal croton-oil-induced inflammation response without
apparent impairment in tissue healing [28].
The use of anti-cancer target agents is increasing, such
as the anti-cancer target drugs blocking the EGF/EGFR
system. It is common to utilize a multi-modal treatment
approach towards solid tumors, often including surgical
resection, and it has become apparent that some targetingagents can impair wound healing or cause increased risk
of perioperative complications, however, a recent article
reviews many of the targeting agents used in solid tumor,
suggesting that up to now, evidence of targeting agents
causing surgical complications is limited [29].
Casacó et al. [30] reported an extensive review about
the effects of anti-epidermal growth factor/epidermal
growth factor receptor therapeutic anti-cancer drugs
on the wound healing process. This review included
the monoclonal antibodies cetuximab, panitumumab
and nimotuzumab; the small tyrosine kinase molecules
erlotinib and gefitinib; the EGF-based cancer vaccine
CIMAvax®; and the EGFR-based cancer vaccine HER-1 vac-
cine, concluding that apparently, there are no deleterious
effects of the anti-EGF/EGFR drugs in the wound healing
post-operative process.
We are reporting the first clinical study of the wound
healing risk associated with surgery after the use of the
therapeutic cancer vaccine, CIMAvax® EGF. The results of
this study show that the following variables: the time using
the vaccine before surgery (a mean time of 22 months),
the time between the last vaccination and surgery
(the mean time was 36 days) and the time between
surgery and the next vaccination (a mean time of 38 days)
did not interfere with proper wound healing. Five of the six
patients operated on started the vaccination six months
before surgery and three patients were vaccinated without
discontinuation treatment for more than two years before
surgery. One of them (patient 1) was vaccinated the
day before surgical treatment. The majority of patients
(four of them) resumed vaccination in a period less than
one month after surgery (See Table 1).
Other endogenous growth factors different from
EGF, such as platelet-derived growth factor (PDGF),
transforming growth factor-alpha (TGF-α), transforming
growth factor-beta (TGF-β), basic fibroblast growth factor
(bFGF), heparin-binding EGF (HB-EGF), and amphiregulin
(AR) also have substantial impact on both epidermal and
dermal wound repair [31-33]. Special interest is focused on
TGF-α, HB-EGF and AR, which also operate by interacting
with the EGFR, and could be responsible for the normal
final wound healing process in these patients.
García et al. [13] measured the antibody titers
against TGFα (an important growth factor involved in
the healing process) in serum of patients treated with
CIMAvax® EGF, looking for the possibility of cross-
reactivity induced by EGF vaccination and they concluded
that no induction of anti-TGFα antibodies and no reduc-
tion of TGFα concentration occurred as a consequence of
EGF vaccination.
Previous studies have shown that serum EGF concen-
trations decreased to undetectable levels in all patients
vaccinated with CIMAvax® EGF [22]. This vaccine causes
a significant inverse correlation between antibody titers
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ation with EGF results in a deprivation of circulating EGF
[12,13]. Additionally, the patients maintain high anti-EGF
antibody titers throughout the time the vaccination is
active, without evidence of immune response exhaustion
[15] and the patients who underwent surgical treatment
did not have any wound healing complications.
Conclusion
The results of this study suggest that apparently the use
of CIMAvax® EGF does not produce a deleterious effect
in the wound healing process as evidenced by the fact
that none of the patients presented adverse events related
with the wound healing process; however we emphasize,
considering the small number of patients who underwent
surgical treatment, that patients receiving CIMAvax®
EGF treatment who undergo surgery should be carefully
monitored during the post-surgical period.
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